Skip to main content

Table 3 Dyspnea Evaluation Based on NYHA classification on Study Days 1 and 14

From: Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial

NYHA Class Placebo/Routine Care Levamisole/ Routine Care
Day 1 Day 14 Day 1 Day 14
N (%) N (%)
Class I (Mild) 12 0 11 0
Class II (Mild) 0 0 0 0
Class III (Moderate) 8 4 8 0
Class IV (Severe) 5 3 6 0
  1. Class I: No limitation of physical activity; Class II: Slight limitation of physical activity; Class III: Marked limitation of physical activity; Class IV: Unable to carry on any physical activity without discomfort [20]
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us